A multi-center, randomized, double-blind, placebo controlled, parallel-group PhaseIIIb study evaluating the effect of inclisiran on atherosclerotic plaque progressionassessed by coronary computed tomography angiography (CCTA) in participantswith a diagnosis of non-obstructive coronary artery disease without previouscardiovascular events
Open
- Protocol code: CKJX839D12303
- EudraCT code: 2021-004601-47
- Research group: Cardiovascular Diseases
- Service: Cardiology
- Principal investigator: Rodríguez Palomares, Jose Fernando
- Pathology: Malalties del sistema circulatori
- Phase: Fase III
- Status: Recruiting volunteers